APOA2 Antibody

What is APOA2 and why is it important in lipoprotein research?

Apolipoprotein A-II (APOA2) is the second most abundant apolipoprotein in high-density lipoprotein (HDL) particles. In humans, the canonical protein has a reported length of 100 amino acid residues and a mass of 11.2 kDa . APOA2 is primarily synthesized by the liver and to a much lesser extent by the intestine. It plays a crucial role in HDL particle synthesis, composition, and function . APOA2 stabilizes HDL structure through its association with lipids and affects HDL metabolism. Research indicates that APOA2 has pleiotropic effects with respect to HDL functionality, adipose tissue metabolism, and glucose utilization . Understanding APOA2 is essential for researchers investigating lipid metabolism disorders, cardiovascular diseases, and metabolic syndromes.

What are the structural differences between human and murine APOA2?

Human and murine APOA2 proteins have dissimilar properties. The main difference is that human APOA2 primarily exists as a dimer in circulation, whereas the murine homolog is a monomer . This structural difference suggests that the role of APOA2 may be quite different in humans and mice, which is important to consider when designing translational research models. Human APOA2 comprises 77 amino acids in its mature form, while there are differences in length and amino acid composition in the murine version . These structural distinctions partially explain the different phenotypes observed in human and mouse models of APOA2 deficiency or overexpression.

What applications are APOA2 antibodies commonly used for in research?

APOA2 antibodies are used in multiple research applications including:

The optimal dilution should be determined experimentally for each application and sample type .

How should I optimize Western blot protocols for APOA2 detection?

For optimal Western blot detection of APOA2:

• Sample preparation: Use plasma samples or cell/tissue lysates with protease inhibitors to prevent degradation.

• Gel selection: Use 12-15% SDS-PAGE gels to resolve the low molecular weight of APOA2 (7-15 kDa).

• Transfer conditions: Use PVDF membrane and optimize transfer time for small proteins (typically shorter than for larger proteins).

• Blocking: 5% non-fat milk or BSA in TBST is typically effective.

• Antibody selection: Choose between monoclonal (higher specificity) and polyclonal (potentially higher sensitivity) based on your experimental needs.

• Expected bands: Look for monomeric APOA2 at 7-9 kDa or dimeric form at approximately 15 kDa .

• Controls: Include human plasma as a positive control.

When interpreting results, note that the observed molecular weight of APOA2 can vary between 7-11 kDa for the monomer, depending on post-translational modifications and gel conditions .

What are the critical parameters for immunohistochemical detection of APOA2 in tissue samples?

For successful immunohistochemical detection of APOA2:

• Tissue fixation: Formalin-fixed, paraffin-embedded sections work well; fresh frozen sections may provide better epitope preservation.

• Antigen retrieval: TE buffer (pH 9.0) is recommended, though citrate buffer (pH 6.0) can be used as an alternative .

• Blocking: Use serum from the same species as the secondary antibody to reduce background.

• Antibody dilution: Start with 1:50-1:500 dilution and optimize .

• Incubation conditions: Incubate primary antibody at 4°C overnight for optimal results.

• Positive controls: Human liver tissue shows strong APOA2 expression and serves as an excellent positive control .

• Negative controls: Omit primary antibody to assess background staining.

• Detection systems: Both chromogenic and fluorescent detection systems are compatible.

Tissue-specific expression patterns should be considered when interpreting results. APOA2 is predominantly expressed in liver, with lower expression in intestine.

How can APOA2 antibodies be used to study APOA2 isoforms in pancreatic cancer research?

APOA2 isoforms have emerged as potential biomarkers for early detection of pancreatic cancer and its precancerous lesions . Research strategies include:

• Isoform characterization: Use antibodies with different epitope specificities to distinguish between APOA2 isoforms (ATQ, AT, and A types).

• Quantitative analysis: Develop sandwich ELISA assays to quantify the plasma concentrations of specific APOA2 isoforms, particularly apoA2-ATQ/AT which has shown diagnostic potential .

• C-terminal processing analysis: Study the unique processing patterns of C-terminal ends of APOA2 homodimers in pancreatic ductal adenocarcinoma using C-terminal specific antibodies.

• APOA2 isoform ratios: Analyze the ratio of oxidized to non-oxidized APOA2 monomers as this has been associated with disease status.

Research has found that pancreatic abnormalities were recognized in about 30% of subjects with an apoA2-ATQ/AT level of ≤35 μg/mL, indicating the potential of this marker for early detection screening .

What experimental approaches can be used to investigate APOA2's role in HDL functionality?

To investigate APOA2's role in HDL functionality:

• Adenovirus-mediated gene transfer: Overexpress human APOA2 in animal models to study its effects on HDL composition and function .

• HDL isolation and fractionation: Separate HDL particles by size or density to study APOA2 distribution across subfractions.

• Cholesterol efflux assays: Measure HDL-stimulated [14C]-Cholesterol efflux from macrophages (e.g., RAW 264.7 cells) to assess how APOA2 affects reverse cholesterol transport .

• Anti-inflammatory activity assessment: Evaluate the effects of APOA2-enriched HDL on LPS-induced inflammation in macrophage cell lines .

• Proteomic analysis: Study how APOA2 expression alters the HDL apoproteome using mass spectrometry.

• Metabolic studies: Perform glucose tolerance and insulin sensitivity tests to link APOA2 levels to metabolic parameters .

Research has shown that APOA2 expression results in distinct changes in HDL apoproteome that correlate with increased antioxidant and anti-inflammatory activities, without affecting cholesterol efflux from macrophages .

What factors might affect the detection of APOA2 in experimental studies?

Several factors can influence APOA2 detection:

• Post-translational modifications: APOA2 undergoes O-glycosylation and phosphorylation that can affect antibody recognition .

• Dimerization state: Human APOA2 primarily exists as dimers, which may not be fully maintained under standard reducing conditions in SDS-PAGE .

• Isoform variety: Multiple APOA2 isoforms exist based on C-terminal processing (ATQ, AT, and A types), which may not all be recognized by the same antibody .

• Oxidative modifications: Methionine oxidation, particularly at Met26, can alter antibody binding and is common in disease states like T2D .

• Sample preparation: Lipid-rich samples may require special extraction protocols to effectively release APOA2.

• Cross-reactivity: Sequence homology between species varies (human APOA2 shares 96% sequence identity with chimpanzee but only 48-66% with bovine, equine, mouse, and rat) .

• Storage conditions: Freeze-thaw cycles can affect protein integrity; aliquoting is recommended for -20°C storage .

How can I distinguish between different APOA2 isoforms in research samples?

To differentiate between APOA2 isoforms:

• Isoform-specific antibodies: Use antibodies targeting the C-terminus where isoforms differ (ATQ, AT, and A variants).

• High-resolution electrophoresis: 2D electrophoresis or specialized SDS-PAGE systems can separate isoforms based on slight charge or size differences.

• Mass spectrometry: LC-MS/MS can accurately identify specific isoforms and post-translational modifications.

• Specific ELISA assays: Sandwich ELISA using isoform-specific capture antibodies can quantify different isoforms .

• Western blotting patterns: Careful analysis of banding patterns on Western blots, as dimeric forms (ATQ/ATQ, ATQ/AT, AT/AT, AT/A, A/A) will appear at slightly different molecular weights.

• C-terminal sequence analysis: Targeted sequencing of the C-terminal region to identify specific truncations.

Research has demonstrated that alterations in APOA2 isoform ratios, particularly apoA2-ATQ/AT levels, correlate with disease states like pancreatic cancer .

How does APOA2 interact with other apolipoproteins in HDL particle formation and function?

APOA2 interactions with other apolipoproteins include:

• APOA2-APOE interactions: APOA2 forms dimers with APOE, affecting APOE's ability to associate with HDL particles . This interaction influences HDL composition and potentially its atherogenic properties.

• APOA1-APOA2 balance: The ratio between APOA1 and APOA2 in HDL particles affects HDL functionality, including cholesterol efflux capacity and anti-inflammatory properties.

• Interactions with APOCs: APOA2 influences the distribution of APOC-I, APOC-II, and APOC-III on HDL particles, which has implications for lipoprotein metabolism.

• HDL subclass distribution: APOA2 expression alters the distribution of HDL subclasses, potentially creating specialized particles like LpA-II:B:C:D:E during acute phase responses .

• Metabolic enzyme interactions: APOA2 may interact with enzymes involved in HDL metabolism, such as lecithin-cholesterol acyltransferase (LCAT) and cholesteryl ester transfer protein (CETP).

Research methodology to investigate these interactions includes co-immunoprecipitation, proximity ligation assays, fluorescence resonance energy transfer (FRET), and lipidomic/proteomic analysis of isolated HDL particles.

What is the relationship between APOA2, immune function, and inflammatory responses?

APOA2's relationship with immune function includes:

• Neutrophil modulation: APOA2 downregulates oxidative burst and cytokine production by human neutrophils, similar to APOA1 .

• Monocyte response regulation: Human APOA2 increases monocyte responses to lipopolysaccharide (LPS) by suppressing LPS-binding protein activity .

• Acute phase response: During infection and inflammation, APOA2 contributes to the formation of specialized LpA-II:B:C:D:E particles with immunoregulatory properties .

• Hepatitis suppression: Administration of APOA2 suppresses Concanavalin A-induced hepatitis in APOA2-deficient mice by reducing IFNγ production by CD4 T cells .

• COVID-19 implications: Decreased APOA2 levels were observed in COVID-19 patients, correlating with disease severity. Native HDL (containing APOA2) exhibited in vitro antiviral activity against SARS-CoV-2 .

Research methodologies include cytokine profiling after APOA2 treatment, immune cell functional assays, animal models of inflammatory diseases with APOA2 modulation, and in vitro infection models to assess antiviral properties.

How can APOA2 antibodies contribute to understanding the SAMD4B-APOA2-PD-L1 axis in cancer immunotherapy?

Recent research has uncovered a SAMD4B-APOA2-PD-L1 axis relevant to cancer immunotherapy :

• Mechanism elucidation: APOA2 antibodies can help validate the regulatory relationship where SAMD4B affects APOA2 mRNA stability through 2'-O-Methylation modification of the C-terminus.

• Protein interaction studies: Co-immunoprecipitation with APOA2 antibodies can confirm the direct interaction between APOA2 and PD-L1.

• Expression correlation analysis: APOA2 antibodies enable immunohistochemical studies to correlate APOA2 expression with PD-L1 levels and CD29+CD8+ T cell infiltration in tumor tissues.

• Therapeutic response prediction: Measuring APOA2 levels before and during immunotherapy may help predict response to treatment targeting this axis.

• Combination therapy development: Understanding APOA2's role in immune evasion could lead to combination therapies targeting both APOA2 and immune checkpoint pathways.

Research has shown that decreased APOA2 attenuates PD-L1 levels through direct interaction, potentially improving the immune microenvironment to achieve antitumor effects . This suggests APOA2 could be a novel target or biomarker for cancer immunotherapy.

What role does APOA2 play in cognitive function and neurodegenerative disorders?

Emerging research suggests APOA2 may be involved in cognitive function:

• Cognitive status correlation: Studies have found that ApoA2 levels are significantly related to cognitive status, with lower levels of ApoA2 associated with better cognitive performance .

• Independent association: After adjusting for control variables, ApoA2 levels were found to be independently associated with cognitive impairment and late-life dementia .

• Comparison with other markers: When studied alongside age, AS levels, POD, IL-6, HDL-C, and ApoC2, ApoA2 remained a significant factor related to cognitive status .

• Potential mechanisms: APOA2 may affect cognitive function through lipid metabolism pathways, inflammatory processes, or direct effects on neural tissues.

• Research approaches: Longitudinal studies measuring APOA2 levels and cognitive assessments, animal models with APOA2 modulation, and brain imaging studies correlated with APOA2 expression can help elucidate these relationships.

Understanding these associations could potentially lead to novel biomarkers for early detection of cognitive decline or therapeutic targets for neurodegenerative disorders.